Finance

Lists
KLBF:IDX
Kalbe Farma Tbk PT
IDR 785.00
+1.29%
(+10.00) 1D
10-р сарын 9, 16:14:38 (GMT+7)  ·   IDR
All symbols
SymbolPriceChange% Change
Generating top insights for KLBF...
Open
IDR 780
High
IDR 795
Low
IDR 770
Mkt. cap
36.75ИН
Avg. vol.
65.83 сая
Volume
0.00
Dividend
2.55%
Quarterly dividend
IDR 5
Ex-dividend date
2026 оны 6-р сарын 4
P/E ratio
9.87
52-wk high
IDR 1,345
52-wk low
IDR 630
EPS
IDR 80
Shares outstanding
46.81 тэрбум
No. of employees
13 мян
Open
IDR 780
High
IDR 795
Low
IDR 770
Mkt. cap
36.75ИН
Avg. vol.
65.83 сая
Volume
0.00
Dividend
2.55%
Quarterly dividend
IDR 5
Ex-dividend date
2026 оны 6-р сарын 4
P/E ratio
9.87
52-wk high
IDR 1,345
52-wk low
IDR 630
EPS
IDR 80
Shares outstanding
46.81 тэрбум
No. of employees
13 мян
News stories
From web sources and news partners
Profile
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise. The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, with a distribution arm that reaches over one million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient. Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Diabetasol, Prenagen, Extra Joss and Fitbar. Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. The name "Kalbe" is a syllabic abbreviation of its founder's name: Khouw Lip Boen. Wikipedia
About Kalbe Farma Tbk PT
CEO-
Employees12.8 мян
Founded1966 оны 9-р сарын 10
Headquarters-
SectorPharmaceutical industry
Last report
2026 оны 7-р сарын 28
Fiscal period
Q2 2026
IDR 19.68 / IDR 20.14
-2.28%miss
Revenue / Est. (IDR)
9.80ИН / -
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in IDR
Loading Previous Earnings...
Revenue
Net income
All values in IDR
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
8.91ИН
9.34ИН
9.68ИН
9.80ИН
Cost of goods sold
5.46ИН
5.92ИН
6.02ИН
6.25ИН
Cost of revenue
5.46ИН
5.92ИН
6.02ИН
6.25ИН
Research and development expenses
98.31 тэрбум
160.88Т
113.14Т
122.60Т
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.51ИН
1.95ИН
2.23ИН
2.27ИН
Operating expense
2.60ИН
2.14ИН
2.33ИН
2.39ИН
Total operating expenses
8.06ИН
8.05ИН
8.36ИН
8.64ИН
Operating income
851.77Т
1.28ИН
1.32ИН
1.16ИН
Other non operating income
-3.78 тэрбум
-4.17 тэрбум
-3.63 тэрбум
-3.74 тэрбум
EBT including unusual items
877.87Т
1.30ИН
1.36ИН
1.19ИН
EBT excluding unusual items
888.55Т
1.30ИН
1.36ИН
1.18ИН
Income tax expense
211.19Т
252.81Т
303.84Т
271.57Т
Effective tax rate
24.06%
19.41%
22.40%
22.80%
Other operating expenses
-7.23 тэрбум
31.35 тэрбум
-10.02 тэрбум
2.13 тэрбум
Net income
656.41Т
1.03ИН
1.03ИН
890.54Т
Net profit margin
7.37%
11.07%
10.63%
9.09%
Earnings per share
14.44
22.72
22.74
19.68
Interest and investment income
41.31 тэрбум
40.43 тэрбум
32.07 тэрбум
43.61 тэрбум
Interest expense
-9.69 тэрбум
-5.77 тэрбум
-4.61 тэрбум
-6.78 тэрбум
Net interest expenses
31.62 тэрбум
34.66 тэрбум
27.46 тэрбум
36.83 тэрбум
Depreciation and amortization charges
-
-
-
-
EBITDA
1.05ИН
1.45ИН
1.51ИН
1.20ИН
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google аппс